Citizen-Petition Ploy Could Become New FDA Bugaboo
Recalling biotechnology battles is almost like re-living boxing matches from the past.
Who could forget when Genzyme Corp. faced off against Transkaryotic Therapies Inc. to get first approval for a Fabry's disease therapy? In a hard-fought showdown, Genzyme had Fabrazyme (agalsidase beta) pitted against TKT's Replagal (agalsidase alfa). At the final bell, the loser was TKT, which gave up efforts to win FDA approval after gaining market clearance in 27 countries, and the FDA gave its nod to Genzyme's drug. Lights out.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter